MassDevice.com +5 | The top 5 medtech stories for September 25, 2017

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. EY is upbeat about the medical device industry: Here’s why The medical device industry is growing, at a healthy and steady pace. This is according to EY’s Pulse of the Industry report, which was released today at AdvaMed’s annual Medtech Conference. “The results of this year’s report is a direct contrast to last year and tells a positive story about the future of the medtech industry,” said EY partner Arda Ural. Read more 4. DeviceTalks Boston: Here’s what you need to know DeviceTalks Boston on Oct 2. will give attendees the chance to see some of the best minds in medtech live. There will be learning and networking opportunities galore. Read on and meet some of the top medical device leaders and experts who will be speaking – and discover other highlights from the upcoming show. Read more 3. Keeping a patient’s lungs clean &expanded after surgery: a Drug Delivery Business News podcast Every year, more than 1 million patients in the U.S. find themselves suffering from respiratory complications following surge...
Source: Mass Device - Category: Medical Devices Authors: Tags: News Well Plus 5 Source Type: news

Related Links:

Risk for heart failure hospital visit declined with statins for women receiving anthracyclines, trastuzumab
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Gynecology, Oncology, Pharmacy, Conference News, Source Type: news
ConclusionTRT can reliably improve global sexual function in men with hypogonadism in the short term. Long ‐term clinical benefits, and safety of TRT in functional hypogonadism, remain to be fully documented. Clinicians should therefore explicitly discuss the uncertainties and benefits of TRT and engage them in shared management decision‐making.
Source: Andrology - Category: Urology & Nephrology Authors: Tags: REVIEW ARTICLE Source Type: research
CONCLUSIONS: Recommendations for addressing the gaps included focusing on non-breast-cancer patients with cardiac toxicity risks, developing precision-based prescriptions based on various medical and physiological characteristics, and adding fatigue symptom experience as an outcome variable. PMID: 32195686 [PubMed - as supplied by publisher]
Source: The Journal of Cardiovascular Nursing - Category: Nursing Authors: Tags: J Cardiovasc Nurs Source Type: research
This article discusses the pathophysiology of cytotoxic-induced HF and presents the risk factors that impair cardiovascular function. The importance of proper assessment and the prophylactic and therapeutic measures in the management of cytotoxic-induced HF are emphasized. The peculiar challenges in the management of cytotoxic-induced HF in Nigeria were also discussed. The need for early involvement of cardiologists by oncologists to improve on the chemotherapeutic and cardiovascular outcome in the management of patients with breast cancer was stressed. Perhaps, it is time to birth a new discipline of cardiooncology in Nigeria.
Source: Annals of African Medicine - Category: African Health Authors: Source Type: research
AbstractBackgroundChemo ‐ and radiotherapy for breast cancer (BC) can lead to cardiotoxicity even years after the initial treatment. The pathophysiology behind these late cardiac effects is poorly understood. Therefore, we studied a large panel of biomarkers from different pathophysiological domains in long‐term BC sur vivors, and compared these to matched controls.Methods and resultsIn total 91 biomarkers were measured in 688 subjects: 342  BC survivors stratified either to treatment with chemotherapy ± radiotherapy (n = 170) or radiotherapy alone (n = 172) and matched controls. Mean age was 59 &t...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
AbstractThe involvement of the right ventricle (RV) in various cardiovascular pathologies is usually explored and demonstrated after thorough research of the left ventricle (LV). This is also true in cardio-oncology, where multimodality imaging with cardiac magnetic resonance and nuclear imaging is essential, but echocardiography plays pivotal role in everyday clinical practice. Chemotherapy and radiotherapy effect on RV has been studied mainly in breast cancer patients and survivors from childhood cancer. Right ventricular geometry and shape limit the ability of classical echocardiographic indices like RV ejection fractio...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
Conclusions: In anthracycline-treated cancer patients, the increase in plasma levels of NT-proBNP and of hs-cTnT can predict the development of anthracycline-induced cardiomyopathy. Early identification of at-risk patients will potentially allow for targeted dose reductions and will diminish the number of patients developing cardiac pathology.
Source: American Journal of Therapeutics - Category: Drugs & Pharmacology Tags: Original Investigations Source Type: research
AbstractBackgroundChemo ‐ and radiotherapy for breast cancer (BC) can lead to cardiotoxicity even years after the initial treatment. The pathophysiology behind these late cardiac effects is poorly understood. Therefore, we studied a large panel of biomarkers from different pathophysiological domains in long‐term BC sur vivors, and compared these to matched controls.Methods and resultsIn total 91 biomarkers were measured in 688 subjects: 342  BC survivors stratified either to treatment with chemotherapy ± radiotherapy (n = 170) or radiotherapy alone (n = 172) and matched controls. Mean age was 59 &t...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
CONCLUSIONS: In this population-based study, aromatase inhibitors were associated with increased risks of heart failure and cardiovascular mortality compared with tamoxifen. There were also trends toward increased risks, although nonsignificant, of myocardial infarction and ischemic stroke. The increased risk of cardiovascular events associated with aromatase inhibitors should be balanced with their favorable clinical benefits compared with tamoxifen. PMID: 32065766 [PubMed - in process]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
ConclusionTRT can reliably improve global sexual function in men with hypogonadism in the short term. Long ‐term clinical benefits, and safety of TRT in functional hypogonadism, remain to be fully documented. Clinicians should therefore explicitly discuss the uncertainties and benefits of TRT and engage them in shared management decision‐making.
Source: Andrology - Category: Urology & Nephrology Authors: Tags: REVIEW ARTICLE Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiac Resynchronization Therapy | Cardiology | China Health | Conferences | Environmental Health | Heart | Heart Failure | Hong Kong Health | Hospitals | Learning | Medical Devices | Orthopaedics | Podcasts | Respiratory Medicine | Universities & Medical Training